Tony Arulanandam
Company: Synaptimmune Therapeutics
Job title: SVP and Head of Research and Development
Seminars:
Overcoming Cell Therapy Resistance to Prevent Relapse in Patients & Promote Durable Responses 9:30 am
Resistance to cell therapies remains one of the most challenging limitations to durable efficacies and long-term responses in the clinic. Unravelling mechanisms of resistance and optimizing innovations in engineering could provide a solution to this major barrier. Analyzing characteristics of relapse to uncover mechanisms of resistance and antigen escape Distinguishing biomarkers to indicate higher risk…Read more
day: Workshop B